Patents by Inventor Maurice P. DeYoung

Maurice P. DeYoung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING CANCER
    Publication number: 20180280470
    Abstract: Methods of treating cancers comprising FGFR1 gene amplification, FGFR1 overexpression, FGFR3 overexpression, FGFR3 amplification, FGF2 overexpression, and/or FGF2 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a FGFR1 ECD and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent. In some embodiments, methods of treating cancers comprising administering a FGFR1 ECD and/or an FGFR1 ECD fusion molecule in combination with at least one chemotherapeutic agent are provided.
    Type: Application
    Filed: January 3, 2018
    Publication date: October 4, 2018
    Applicants: Five Prime Therapeutics, Inc., GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Julie Hambleton, Maureen Bleam, Maurice P. DeYoung, Geraldine Ferron-Brady, Rakesh Kumar, Lone Ottesen
  • Methods of treating mesothelioma by administration of compounds comprising FGFR1 ECD
    Patent number: 9775881
    Abstract: Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule are provided. Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule and at least one anti-angiogenic agent are provided.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: October 3, 2017
    Assignees: Five Prime Therapeutics, Inc., GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: David Bellovin, Kevin Baker, Thomas Brennan, Arundathy Nirmalini Pandite, Bijoyesh Mookerjee, Maurice P. DeYoung, Rakesh Kumar
  • METHODS OF TREATING CANCER
    Publication number: 20160106809
    Abstract: Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule are provided. Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule and at least one anti-angiogenic agent are provided.
    Type: Application
    Filed: May 22, 2014
    Publication date: April 21, 2016
    Inventors: David Bellovin, Kevin Baker, Thomas Brennan, Arundathy Nirmalini Pandite, Bijoyesh Mookerjee, Maurice P. DeYoung, Rakesh Kumar
  • METHODS OF TREATING CANCER
    Publication number: 20160067307
    Abstract: Methods of treating cancers comprising FGFR1 gene amplification, FGFR1 overexpression, FGFR3 overexpression, FGFR3 amplification, FGF2 overexpression, and/or FGF2 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a FGFR1 ECD and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent. In some embodiments, methods of treating cancers comprising administering a FGFR1 ECD and/or an FGFR1 ECD fusion molecule in combination with at least one chemotherapeutic agent are provided.
    Type: Application
    Filed: April 30, 2014
    Publication date: March 10, 2016
    Inventors: Julie Hambleton, Maureen R. Bleam, Maurice P. DeYoung, Geraldine Ferron-Brady, Rakesh Kumar, Lone Ottesen